Disease · EFO_0008626
vitreous hemorrhage
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. vitreous hemorrhage. Diseases, record EFO_0008626. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0008626
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Blood In Vitreous, Blood In Vitreous Fluid,, Vitreous Fluid, Blood In, Vitreous Hemorrhage Fluid, vitreous body hemorrhage
- Open Targets
Drugs7
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| HYALURONIDASE (OVINE) | CHEMBL2108607 | Enzyme | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
| PEGAPTANIB SODIUM | CHEMBL1201421 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RANIBIZUMAB | CHEMBL1201825 | Antibody | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| AFLIBERCEPT | CHEMBL1742982 | Protein | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HYALURONIDASE | CHEMBL1201636 | Enzyme | Unknown | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
Targets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | 4 | Vascular endothelial growth factor A antagonist; Vascular endothelial growth factor A inhibitor | Phase 3 | https://conductscience.org/library/genes/7422 | Drugs and targets |
| PGF | Placenta growth factor | 1 | Placenta growth factor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5228 | Drugs and targets |
Trials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00996437 | Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N) | Phase 2/3 | 261 | 2013-05-16 | Vitreous Hemorrhage, Proliferative Diabetic Retinopathy | RANIBIZUMAB, SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02858076 | Anti-VEGF vs. Prompt Vitrectomy for VH From PDR | Phase 2/3 | 205 | 2021-01-19 | Proliferative Diabetic Retinopathy, Vitreous Hemorrhage | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT05248334 | A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy | Phase 1 | 120 | Diabetic Retinopathy, Postoperative Recurrent Vitreous Hemorrhage, Pars Plana Vitrectomy, Ranibizumab | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00596297 | Preoperative Bevacizumab for Vitreous Hemorrhage | Phase 1/2 | 16 | Diabetic Retinopathy, Vitreous Hemorrhage | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00656435 | Bevacizumab and Long Acting Gas in Diabetic Vitrectomy | Phase 3 | 16 | Proliferative Diabetic Retinopathy | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01091896 | Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage | Phase 2 | 1 | Vitreous Hemorrhage Secondary to PDR | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01589718 | A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy | Phase 3 | 0 | Proliferative Diabetic Retinopathy | PEGAPTANIB SODIUM | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ranibizumab vs Saline Injection: serious adverse events | 13 of 125 | 23 of 136 | 261 | NCT00996437 | Trial comparisons |
| Intravitreous 2 mg Aflibercept Injections vs Prompt Vitrectomy Plus Panretinal Photocoagulation: deaths from any cause | 6 of 100 | 3 of 105 | 205 | NCT02858076 | Trial comparisons |
| Intravitreous 2 mg Aflibercept Injections vs Prompt Vitrectomy Plus Panretinal Photocoagulation: serious adverse events | 44 of 100 | 45 of 105 | 205 | NCT02858076 | Trial comparisons |
| Intravitreous 2 mg Aflibercept Injections vs Prompt Vitrectomy Plus Panretinal Photocoagulation: Recurrent Vitreous Hemorrhage | 48 of 97 | 16 of 104 | 201 | NCT02858076 | Trial comparisons |
| Intravitreous 2 mg Aflibercept Injections vs Prompt Vitrectomy Plus Panretinal Photocoagulation: Retinal Neovascularization on Clinical Exam | 15 of 89 | 2 of 95 | 184 | NCT02858076 | Trial comparisons |
| Intravitreous 2 mg Aflibercept Injections vs Prompt Vitrectomy Plus Panretinal Photocoagulation: Retinal Neovascularization on Clinical Exam | 25 of 85 | 3 of 92 | 177 | NCT02858076 | Trial comparisons |
| Intravitreous 2 mg Aflibercept Injections vs Prompt Vitrectomy Plus Panretinal Photocoagulation: Retinal Neovascularization on Clinical Exam | 20 of 88 | 2 of 83 | 171 | NCT02858076 | Trial comparisons |
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0008626
GET https://conductscience.org/api/diseases/v1/EFO_0008626/drugs